|
Tuesday, 25 October 2011 06:41 |
|
PARIS--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the appointment of David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1, 2011. He will report to Christopher A. Viehbacher, Chief Executive Officer of Sanofi, and will join the Group Management Committee. Christopher A. Viehbacher will retain the position of Chairman, Genzyme. |
|
Read more...
|
|
Wednesday, 19 October 2011 00:44 |
 Sentrx, the leading provider of drug safety services to the life sciences industry, and the largest hosting provider of the Oracle Argus Safety Suite announced today that Charles T. Saldarini has resigned his position as CEO and Chairman of the Board to pursue efforts with his own company, The Charles T. Saldarini Group.
|
|
Read more...
|
|
Monday, 17 October 2011 00:22 |
 Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Robert A. Bradway to the Company's Board. Bradway, 48, is Amgen's president and chief operating officer. The addition of Bradway brings the number of Amgen board members to 13.
|
|
Read more...
|
|
Friday, 14 October 2011 00:54 |
 Isis Biopolymer announced the appointment of Chris Hobson as its new president and chief executive officer, effective October 1, 2011. Concurrently, Mr. Hobson has been appointed to the Isis Biopolymer board of directors.
|
|
Read more...
|
|
Wednesday, 12 October 2011 00:46 |
 On October 1st, Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joined the management board of apceth GmbH & Co. KG, Munich. Ralf Huss will focus on the pre-clinical and early development of cell-based therapeutics and external innovation in the company that is specialized on the translational development and manufacturing of innovative cell therapy products.
|
|
Read more...
|
|
Monday, 10 October 2011 00:08 |
|
 Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it has added Michael Yeadon, PhD, to the company’s Scientific Advisory Board to offer expertise as the company accelerates its research and clinical programs.
|
|
Read more...
|
|
Friday, 30 September 2011 00:48 |
 Achaogen, Inc., a biopharmaceutical company discovering and developing treatments for life-threatening, multi-drug resistant (MDR) Gram-negative bacterial infections, announced today that the company's board of directors has appointed Kenneth J. Hillan, M.B. Ch.B., the company’s chief medical officer, to succeed J. Kevin Judice, Ph.D., as chief executive officer and member of the board of directors effective October 3, 2011. Dr. Hillan will continue in his role as chief medical officer of the company.
|
|
Read more...
|
|
Wednesday, 28 September 2011 00:56 |
 Medivir AB (OMX: MVIR), an emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the board has appointed Maris Hartmanis as new President and CEO.
|
|
Read more...
|
|
Monday, 26 September 2011 00:34 |
 Bausch + Lomb, the global eye health company, has named Sheila Hopkins Global President of the company's Vision Care business, and two of the company's senior executives Peter Valenti III and Steven Robins have assumed new roles within the organization.
|
|
Read more...
|
|
Friday, 23 September 2011 00:58 |
 Third Rock Ventures, LLC, a venture capital firm focused on building life sciences companies, today announced that Keith E. Dionne, Ph.D., has joined Third Rock as an entrepreneur-in-residence (EIR). As an EIR, Dr. Dionne will provide strategic input on new and existing portfolio companies with a particular focus on rare genetic diseases and novel biologics.
|
|
Read more...
|
|
|
Wednesday, 19 October 2011 00:47 |
 DIA announces the appointment of Kaushik Desai as Director of DIA India. Kaushik brings to DIA both a deep knowledge of the global regulatory framework and the pharmaceutical environment in India as well as a passion for the vision and mission of the association.
|
|
Read more...
|
|
Monday, 17 October 2011 00:27 |
|
 EKR Therapeutics, Inc. a privately held specialty pharmaceutical company, announced today that Rolf A. Classon, chairman of the board and independent director, will not stand for reelection and has resigned effective immediately.
|
|
Read more...
|
|
Friday, 14 October 2011 00:57 |
|
 Samantha Du, PhD has quietly retired as CEO of Hutchison MediPharma and Chief Scientific Officer of its parent, Hutchison Chi-Med. She plans to take a few months off while she evaluates her next career move.
|
|
Read more...
|
|
Wednesday, 12 October 2011 00:56 |
|
RedHill Biopharma Ltd. (TASE:RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage patented new formulations and combinations of existing drugs, announced the appointment of Professor David Y. Graham, MD, as the lead investigator of the Company's planned pivotal US clinical trial with RHB-104, its proprietary therapy for Crohn's disease. In this role, Prof. Graham will have broad responsibilities in the design of the clinical trial and will be actively involved in its execution and in the publication of its results.
|
|
Read more...
|
|
Monday, 10 October 2011 00:10 |
|
The BioIndustry Association (BIA) has today appointed Janis Clayton, Keith Martin, Diana Sternfeld and Ian Tomlinson to its Board of Directors at its Annual General Meeting. In addition, John Brown, Jeremy Haigh, Stephen Harris, Edward Hodgkin, Geoff Newman, Peter Nolan and Sam Williams have been re-appointed. The new Board members will serve from1 January 2012.
|
|
Read more...
|
|
Saturday, 08 October 2011 01:07 |
 The Board of Directors of Immucor, Inc. announced today that William A. Hawkins will be Immucor's next CEO. Immucor, Inc. is a private company, wholly owned by TPG Capital. Mr. Hawkins' appointment follows the decision of current CEO Joshua Levine to step down from his role. The transition will be effective October 17, 2011.
|
|
Read more...
|
|
Friday, 30 September 2011 00:20 |
|
 Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Brian Holzer to the position of Executive Director of Brand Management. Dr. Holzer will report to Rick Gonzalez, Vice President of Business Solutions and Government Affairs. He will be primarily responsible for leading and managing Spectrum’s cross-functional brand efforts for FUSILEV® and ZEVALIN® as well as brand planning for apaziquone and belinostat, Spectrum’s late-stage drugs in development.
|
|
Read more...
|
|
Wednesday, 28 September 2011 00:00 |
 ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has appointed Dr. Mike Bartley to the Management Board as Chief Development Officer. In this role, Dr. Bartley will lead the preclinical and clinical development activities at ProtAffin.
|
|
Read more...
|
|
Monday, 26 September 2011 00:32 |
 NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, today announced that Bill Wedlake, NextPharma?s Chief Executive Officer will step down effective 30th September, 2011.
|
|
Read more...
|
|
Friday, 23 September 2011 00:05 |
|
 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI), an international pharmaceutical company, today announced that Greg Deener has joined Sucampo Pharma Americas, Inc. (SPA), its wholly-owned subsidiary, as Vice President of Marketing, Strategy & Implementation.
|
|
Read more...
|
|
